A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 796 participants.
Also called NCT06034743
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 796 participants
- Sponsor
- Registry
-
NCT06034743 -
2023-505499-32-00
-
- Other papers using this trial's data
- Efficacy and Safety of Baxdrostat in Uncontrolled and Resistant Hypertension
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Denmark, France, Germany, Hungary, India, Israel, Italy, Japan, Malaysia, Netherlands, Poland, Slovakia, South Africa, South Korea, Spain, Sweden, Taiwan, Thailand, Türkiye, United Kingdom, Vietnam
- Registry status
- Completed
Technical summary
Registry record NCT06034743. Randomized; quadruple masking; primary purpose treatment. Start 2023-11-22 (actual); primary completion 2025-05-21 (actual). Results posted on 2026-07-30.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Investigate the Efficacy and Safety of Baxdrostat in Participants With Uncontrolled Hypertension on Two or More Medications Including Participants With Resistant Hypertension
- Acronym
- BaxHTN
- Condition
- Uncontrolled Hypertension
- Condition
- Resistant Hypertension
- Intervention (Drug)
- Baxdrostat
- Intervention (Drug)
- Placebo
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct06034743- Content hash
89d9a5ec6836f22a1f4b6a90442e5b148a852670e94931eb2bb762c15e1ddb7a